IMFINZI 50 mg/mL concentrate for solution for infusion.
D933RC00002
Phase 2 small_molecule active
Quick answer
IMFINZI 50 mg/mL concentrate for solution for infusion. for Patients With Muscle-Invasive Bladder Cancer is a Phase 2 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Patients With Muscle-Invasive Bladder Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active